ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Shimada H, Nabeya Y, Okazumi S, et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.

    Article  Google Scholar 

  2. 2.

    Okamura A, Matsuda S, Mayanagi S, et al. Clinical significance of pretherapeutic serum squamous cell carcinoma antigen level in patients with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08716-y.

    Article  PubMed  Google Scholar 

  3. 3.

    Yokota T, Kato K, Hamamoto Y, et al. A 3–year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27:460–7.

    Article  Google Scholar 

  4. 4.

    Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.

    Article  Google Scholar 

  5. 5.

    Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–17.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Masayuki Watanabe MD, PhD.

Ethics declarations

Disclosure

None declared conflicts of interests for this study. Conflicts of interests outside this work are as follows; Yuko Kitagawa received research funding from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Merck Serono, Asahi Kasei, EA Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical Factory, Shionogi, Kaken Pharmaceutical, Kowa Pharmaceutical, Astellas Pharma, Medicon, Dainippon Sumitomo Pharma, Taisho Toyama Pharmaceutical, Kyouwa Hakkou Kirin, Pfizer Japan, Ono Pharmaceutical, Nihon Pharmaceutical, Japan Blood Products Organization, Medtronic Japan, Sanofi K.K. grants from Eisai, Tsumura, KCI Licensing, Abbott Japan, and Fujifilm Toyama Chemical.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Okamura, A., Matsuda, S., Kawakubo, H. et al. ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol (2020). https://doi.org/10.1245/s10434-020-08772-4

Download citation